
<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <title>Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial. | Aparicio Lab</title>
    
    <meta name="author" content="Dr. Samuel Aparicio">

    <!-- Enable responsive viewport -->
    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>

    <!-- Bootstrap styles -->
    <link href="/assets/themes/lab/bootstrap/css/bootstrap.min.css" rel="stylesheet"/>
    <!-- Optional theme -->
    <link href="/assets/themes/lab/bootstrap/css/bootstrap-theme.min.css" rel="stylesheet"/>
    <!-- Sticky Footer -->
    <link href="/assets/themes/lab/bootstrap/css/bs-sticky-footer.css" rel="stylesheet"/>

    <!-- Custom styles -->
    <link href="/assets/themes/lab/css/style.css?body=1" rel="stylesheet" type="text/css" media="all"/>

    <!-- icon -->
    <link rel="icon" type="image/png" href="/assets/themes/lab/images/logo/favicon.png"/>

    <!-- Custom fonts and icons via Font Awesome, http://fortawesome.github.io/Font-Awesome/ -->
    <link rel="stylesheet" href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css"/>

    <!-- Fonts via Google -->
    <link href='https://fonts.googleapis.com/css?family=Lato:300italic,700italic,300,700' rel='stylesheet' type='text/css'/>

    <!-- Math via MathJax -->
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>


    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <!-- Fav and touch icons -->
    <!-- Update these with your own images
      <link rel="shortcut icon" href="images/favicon.ico">
      <link rel="apple-touch-icon" href="images/apple-touch-icon.png">
      <link rel="apple-touch-icon" sizes="72x72" href="images/apple-touch-icon-72x72.png">
      <link rel="apple-touch-icon" sizes="114x114" href="images/apple-touch-icon-114x114.png">
    -->

    <!-- atom & rss feed
    <link href="/atom.xml" type="application/atom+xml" rel="alternate" title="Sitewide ATOM Feed">
    <link href="/rss.xml" type="application/rss+xml" rel="alternate" title="Sitewide RSS Feed">
    -->

  </head>

  <body>

  <!-- Static top navbar -->

  <nav class="navbar navbar-expand-lg navbar-light bg-light">
    <div class='col-sm-1'></div>
    <a href="/">
      <img class="pull-left logo" src="/assets/themes/lab/images/logo/lab-logo.svg" type="image/svg+xml">
    </a>
    
    
    
    <a class="navbar-brand" href="/">Aparicio Lab</a>
    
      
      <div class="collapse navbar-collapse" id="navbarNav">
        <ul class="navbar-nav">
          <div class="navbar-collapse collapse w-100 order-3 dual-collapse2">
            <ul class="navbar-nav ml-auto">
              <li class="nav-item">
                <a class="nav-link" href="/careers">Careers</a>
              </li>
              <li class="nav-item">
                <a class="nav-link" href="/research">Research</a>
              </li>
              <li class="nav-item">
                <a class="nav-link" href="/team">Team</a>
              </li>
              <li class="nav-item">
                <a class="nav-link" href="/papers">Papers</a>
              </li>
              </ul>
          </div>

        </ul>
      </div>
    </div>
    <div class='col-sm-1'></div>
  </nav>

  <div class='container'>
      <!-- Brand and toggle get grouped for better mobile display-->

      <!-- Collect the nav links, forms, and other content for toggling 
      

        <ul class="nav navbar-nav navbar-right pull-right">
          
          
          


  
    
  
    
      
    
  
    
  
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
  
    
  
    
      
      	
      	<li><a href="/careers">Research</a></li>
      	
      
    
  
    
      
      	
      	<li><a href="/research">Research</a></li>
      	
      
    
  
    
      
      	
      	<li><a href="/papers/">Papers</a></li>
      	
      
    
  
    
      
      	
      	<li><a href="/team/">Team</a></li>
      	
      
    
  



-->

   <!-- Content -->
   <div class="container">
      
<!-- 
Branched from Trevor Bedford's source, https://github.com/blab/blotter/blob/master/_layouts/paper.html
with gratitude.
-->

<div class="bigspacer"></div>

<div class="row">
	<div class="col-md-3">
		<div class="media">
			
			<img class="pull-left pad-right media-object paper-image" src="/assets/images/papers/32910476.jpg">
			
		</div>
	</div>

	<div class="col-md-9">
		<div class="media-body titlebox">
			<div class="title media-heading">
				Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.
			</div>
			<p>
			<div class="smallhead">
				Prashanth Moku, Lois Shepherd, Suhail M Ali, Kim Leitzel, Wendy R Parulekar, Liting Zhu, Shakeel Virk, Dora Nomikos, Samuel Aparicio, Karen Gelmon, Joe Drabick, Leah Cream, E Scott Halstead, Todd M Umstead, Dan Mckeone, Hyma Polimera, Ashok Maddukuri, Aamnah Ali, Vinod Nagabhairu, Joyson Poulose, Neha Pancholy, Howard Spiegel, Bingshu E Chen, Allan Lipton, 
				<span class="journal">
				Cancer <b>126</b>, 4859-4866 (2020)
				</span>
				
				
				
				
			</div>
		</div>
	</div>
</div>

<div class="bigspacer"></div>

<div class="row">
	<div class="col-md-3">
		<div class="bigspacer"></div>
		<div class="glyphbox note"> <!-- DAD: what is this class? -->
			

			

			
						
			
			<div class="smallhead subtle">
				DOI
			</div>
			<div class="pad-left note">
				<div class="smallspacer"></div>
				<i class="fa fa-external-link fa-fw"></i>
				<a class="off" href="http://dx.doi.org/10.1002/cncr.33149">10.1002/cncr.33149</a>
			</div>
			<div class="bigspacer"></div>			
			
			
			
			
			
			
			<div class="smallhead subtle">
				Share
			</div>
		    <!-- Paste the 3 next lines where you want the sharing button(s) to appear -->
		    <div class="post-sharing">
		     

  
  		<!-- Twitter -->
<i class="fa fa-twitter fa-fw"></i>
<a class="off" href="https://twitter.com/share?url=&text=" data-text="Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial." data-via="" data-related="sajraparicio" target="_blank">tweet</a>

	


		    </div>

		</div>
	</div>
	
	<div class="col-md-8">	
		<div class="post">
			<p><br /></p>
<div data-badge-popover="right" data-badge-type="donut" data-pmid="32910476" data-hide-no-mentions="true" class="altmetric-embed"></div>

<h1 id="abstract">Abstract</h1>

<p>The purpose of this retrospective biomarker study of the Canadian Cancer Trials Group (CCTG) MA.31 randomized phase 3 trial (lapatinib vs trastuzumab) of HER2-positive metastatic breast cancer (MBC) was to evaluate the prognostic and predictive biomarker utility of pretreatment serum programmed death ligand 1 (PD-L1) levels.</p>

<p>CCTG MA.31 accrued 652 HER2-positive patients; 387 had serum available (185 in the trastuzumab arm and 202 in the lapatinib arm). The Ella immunoassay platform (ProteinSimple, San Jose, California) was used to quantitate serum PD-L1 levels. Stepwise forward Cox multivariable analyses were performed for progression-free survival and overall survival (OS).</p>

<p>In the whole trial population, continuous pretreatment serum PD-L1 levels were not associated with OS. However, within the trastuzumab arm, a higher continuous pretreatment serum PD-L1 level was significant for shorter OS (hazard ratio [HR], 3.85; P = .04), but within the lapatinib arm, pretreatment serum PD-L1 was not associated with OS (P = .37). In the whole trial, in a multivariable analysis for OS, serum PD-L1 (median cut point) remained a significant independent covariate (HR, 2.38; P = .001). There was a significant interaction between treatment arm and continuous serum PD-L1 (bootstrap method; P = .0025): at or above 214.2 pg/mL (the 89th percentile), serum PD-L1 was associated with significantly shorter OS with trastuzumab treatment versus lapatinib treatment.</p>

<p>In the CCTG MA.31 trial, serum PD-L1 was a significant predictive factor: a higher pretreatment serum PD-L1 level was associated with shorter OS with trastuzumab treatment but with longer OS with lapatinib treatment. Immune evasion may decrease the effectiveness of trastuzumab therapy. Further evaluation of elevated serum PD-L1 in advanced breast cancer is warranted to identify patients with HER2-positive MBC who may benefit from novel immune-targeted therapies in addition to trastuzumab.</p>


		</div>	
	</div>
	

	<div class="col-md-1"></div>
</div>

<div class="bigspacer"></div>



   </div>


  <!-- Static bottom navbar -->
  <nav class="navbar navbar-expand-lg navbar-light bg-light navbar-fixed-bottom">
    <div class="container-fluid">
      <!-- Collect the nav links, forms, and other content for toggling -->
      <div class="collapse navbar-collapse" id="jb-bottom-collapse">
        
        <div class = "col-md-2">
        <a class="logo-anchor" href="">
          <img class="logo" alt="" src="">
        </a>
        <a class="logo-anchor" href="http://www.bccancer.bc.ca/">
          <img class="logo" alt="BC Cancer" src="/assets/images/logos/bc_cancer.png">
        </a>
        <a class="logo-anchor" href="http://www.ubc.ca/">
          <img class="logo" alt="UBC" src="/assets/images/logos/ubc.png">
        </a>
        </div>
        <div class = "col-md-8"></div>
        <div class = 'float-right col-md-2'>
          <ul class="nav navbar-nav navbar-right navbar-small">
            <li><a href='/contact'>Contact</a></li>
          </ul>
      </div>
      </div><!-- /.navbar-collapse -->
    </div>
  </nav>

    




  <script type="text/javascript">
  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', 'UA-103919622-1']);
  _gaq.push(['_trackPageview']);

  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();
</script>




    <!-- Latest compiled and minified JavaScript, requires jQuery 1.x (2.x not supported in IE8) -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
    <script src="/assets/themes/lab/bootstrap/js/bootstrap.min.js"></script>
    <script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'></script>
  </body>
</html>

